ESPRIT Study in Hypogonadal Men

NCT01143818 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1053

Last updated 2011-10-17

Study results available
· View outcomes & findings →

Summary

Observational study with AndroGel®, Testosterone 1% gel therapy (ESPRIT) in hypogonadal men in the community over 6 months.

Conditions

  • Hypogonadism

Interventions

DRUG

AndroGel (testosterone gel) 1%

AndroGel is topical testosterone gel 1% and is prescribed for once daily use.

Sponsors & Collaborators

  • Fovea

    collaborator OTHER
  • Abbott

    lead INDUSTRY

Principal Investigators

  • Michael Miller, PharmD · Abbott

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • Canada
  • Croatia
  • Germany
  • Kuwait
  • Romania
  • Russia
  • Saudi Arabia
  • Slovenia
  • United Arab Emirates

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01143818 on ClinicalTrials.gov